Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Computer-assisted management of early rheumatoid arthritis-II: does prednisone inhibit progression of joint damage if early RA [rheumatoid arthritis] is treated very intensively with disease modifying antirheumatic drugs (DMARDs)?

Trial Profile

Computer-assisted management of early rheumatoid arthritis-II: does prednisone inhibit progression of joint damage if early RA [rheumatoid arthritis] is treated very intensively with disease modifying antirheumatic drugs (DMARDs)?

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prednisone (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms CAMERA-II
  • Most Recent Events

    • 06 Mar 2012 Primary endpoint 'Radiographic-outcomes' has been met.
    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top